

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Withdrawn) A substantially pure polypeptide complex comprising a Clostridium botulinum neurotoxin and more than one Clostridium botulinum type E neurotoxin associate polypeptide.

2-6. (Canceled)

7. (Withdrawn) A substantially pure Clostridium botulinum serotype E neurotoxin associated polypeptide.

8-16. (Canceled)

17. (Withdrawn) A substantially pure antibody that specifically binds to a Clostridium botulinum type E neurotoxin associated polypeptide having a molecular weight of approximately 80, 60, 45, or 18 kDa, or to a complex of any two or more of said neurotoxin associated polypeptides.

18. (Withdrawn) A substantially pure antibody that specifically binds to a polypeptide complex of claim 1.

19. (Withdrawn) A method of detecting a serotype E neurotoxin complex in a sample, the method comprising:

(a) contacting the sample with an antibody of claim 17, and

(b) detecting antibody-bound polypeptide, if any, in the sample, the presence of antibody-bound polypeptide indicating the presence of serotype E neurotoxin in the sample.

20. (Withdrawn) The method of claim 19, wherein the sample is a foodstuff.

21. (Withdrawn) The method of claim 19, wherein the sample is a gastrointestinal, blood, or tissue sample obtained from a vertebrate animal.

22. (Presently Amended) A method of treating a patient who is suffering from a disease or condition associated with ~~excessive~~ exaggerated release of acetylcholine from presynaptic nerve terminals, the method comprising administering to the patient a therapeutically effective amount of a composition comprising a substantially pure polypeptide complex of claim 1 comprising a Clostridium botulinum neurotoxin and one or more Clostridium botulinum type E neurotoxin associated polypeptide selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO:4, a polypeptide comprising the amino acid sequence of SEQ ID NO:3, a polypeptide comprising the amino acid sequence of SEQ ID NO:2, a polypeptide comprising the amino acid sequence of SEQ ID NO:1, and a polypeptide comprising the amino acid sequence of SEQ ID NO:5.

23. (Original) The method of claim 22, wherein the excessive acetylcholine release causes undesirable contraction of smooth or skeletal muscle cells.

24. (Original) The method of claim 22, wherein the excessive release of acetylcholine causes profuse sweating, lacrimation, or mucous secretion.

25. (Withdrawn) A method of treating a patient who is suffering from spasticity occurring secondary to brain ischemia, or traumatic injury of the brain or spinal cord, the method

comprising administering to the patient a therapeutically effective amount of a polypeptide complex of claim 1.

26. (Withdrawn) A method of treating a patient who is suffering from tension headache or pain, the method comprising administering to the patient a therapeutically effective amount of a polypeptide complex of claim 1.

27-29. (Canceled)

30. (Withdrawn) A method of detecting a Clostridium botulinum serotype E neurotoxin in a sample, the method comprising:

(a) contacting the sample with a Clostridium botulinum type E neurotoxin associated polypeptide (NAP) of claim 7 that specifically binds a serotype E botulinum neurotoxin and thereby forms a NAP-neurotoxin complex, and

(b) detecting the NAP-neurotoxin complex, if any, in the sample, the presence of a complex indicating the presence of serotype E neurotoxin in the sample.

31-32. (Canceled)

33. (New) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:4.

34. (New) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:3.

35. (New) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:2.

36. (New) The method of claim 22, wherein the neurotoxin associated polypeptide

comprises the amino acid sequence of SEQ ID NO:1.

37. (New) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:5.